+

WO2007014744A3 - C-terminal tnf-family ligand (ctl) -prodrug - Google Patents

C-terminal tnf-family ligand (ctl) -prodrug Download PDF

Info

Publication number
WO2007014744A3
WO2007014744A3 PCT/EP2006/007581 EP2006007581W WO2007014744A3 WO 2007014744 A3 WO2007014744 A3 WO 2007014744A3 EP 2006007581 W EP2006007581 W EP 2006007581W WO 2007014744 A3 WO2007014744 A3 WO 2007014744A3
Authority
WO
WIPO (PCT)
Prior art keywords
region
ctl
prodrug
family ligand
terminal
Prior art date
Application number
PCT/EP2006/007581
Other languages
French (fr)
Other versions
WO2007014744A2 (en
Inventor
Klaus Pfizenmaier
Harald Wajant
Iris Watermann
Jeannette Gerspach
Dafne Mueller
Original Assignee
Univ Stuttgart
Univ Wuerzburg J Maximilians
Klaus Pfizenmaier
Harald Wajant
Iris Watermann
Jeannette Gerspach
Dafne Mueller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Stuttgart, Univ Wuerzburg J Maximilians, Klaus Pfizenmaier, Harald Wajant, Iris Watermann, Jeannette Gerspach, Dafne Mueller filed Critical Univ Stuttgart
Publication of WO2007014744A2 publication Critical patent/WO2007014744A2/en
Publication of WO2007014744A3 publication Critical patent/WO2007014744A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to a polypeptide with preferably antitumoral and/or immune modulating cytokine properties which can be activated via in vivo processing comprising a C-terminal region having specific biological activity, wherein at the N-terminus of said C-terminal region an inhibitory region, a region having a processing site, and a region which is capable of selectively recognising a macromolecule on a cell surface or a component of the extracellular matrix is arranged.
PCT/EP2006/007581 2005-08-03 2006-07-31 C-terminal tnf-family ligand (ctl) -prodrug WO2007014744A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005036542A DE102005036542A1 (en) 2005-08-03 2005-08-03 CTL prodrug
DE102005036542.6 2005-08-03

Publications (2)

Publication Number Publication Date
WO2007014744A2 WO2007014744A2 (en) 2007-02-08
WO2007014744A3 true WO2007014744A3 (en) 2007-04-12

Family

ID=37560705

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/007581 WO2007014744A2 (en) 2005-08-03 2006-07-31 C-terminal tnf-family ligand (ctl) -prodrug

Country Status (2)

Country Link
DE (1) DE102005036542A1 (en)
WO (1) WO2007014744A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9169321B2 (en) 2007-08-22 2015-10-27 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1972350A1 (en) * 2007-03-20 2008-09-24 Rijksuniversiteit Groningen Dual targeting system
EP2009022A1 (en) * 2007-06-26 2008-12-31 Apogenix GmbH Trimeric death ligands with enhanced activity (tenascin)
EP2020249A1 (en) 2007-08-01 2009-02-04 Boehringer Ingelheim Pharma GmbH & Co. KG Inhalator
US8895702B2 (en) 2008-12-08 2014-11-25 City Of Hope Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies
CA2749339A1 (en) 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
US8399219B2 (en) 2009-02-23 2013-03-19 Cytomx Therapeutics, Inc. Protease activatable interferon alpha proprotein
MX2011010763A (en) 2009-04-17 2011-12-16 Basf Plant Science Co Gmbh Plant promoter operable in endosperm and uses thereof.
AU2011309689B2 (en) 2010-09-28 2015-01-15 Hadasit Medical Research Services & Development Ltd. Compositions and methods for treatment of hematological malignancies
WO2012130471A1 (en) * 2011-04-01 2012-10-04 Universität Stuttgart Recombinant tnf ligand family member polypeptides with antibody binding domain and uses thereof
GB201402006D0 (en) 2014-02-06 2014-03-26 Oncomatryx Biopharma S L Antibody-drug conjugates and immunotoxins
RS61870B1 (en) 2014-11-14 2021-06-30 Hoffmann La Roche Antigen binding molecules comprising a tnf family ligand trimer
CN114751989B (en) 2015-03-31 2025-03-14 豪夫迈·罗氏有限公司 Antigen binding molecules comprising trimeric TNF family ligands
AR106188A1 (en) 2015-10-01 2017-12-20 Hoffmann La Roche ANTI-CD19 HUMANIZED HUMAN ANTIBODIES AND METHODS OF USE
EP3231813A1 (en) * 2016-03-29 2017-10-18 F. Hoffmann-La Roche AG Trimeric costimulatory tnf family ligand-containing antigen binding molecules
WO2018178074A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Trimeric antigen binding molecules specific for a costimulatory tnf receptor
WO2020260368A1 (en) 2019-06-24 2020-12-30 Universität Stuttgart Tnfr2 agonists with improved stability
WO2021097376A1 (en) * 2019-11-14 2021-05-20 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022833A1 (en) * 2000-09-15 2002-03-21 Universität Stuttgart Fusion protein from antibody cytokine-cytokine inhibitor (selectokine) for use as target-specific prodrug

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022833A1 (en) * 2000-09-15 2002-03-21 Universität Stuttgart Fusion protein from antibody cytokine-cytokine inhibitor (selectokine) for use as target-specific prodrug

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GERSPACH J ET AL: "Restoration of membrane TNF-like activity by cell surface targeting and matrix metalloproteinase-mediated processing of a TNF prodrug.", CELL DEATH AND DIFFERENTIATION. FEB 2006, vol. 13, no. 2, February 2006 (2006-02-01), pages 273 - 284, XP002413275, ISSN: 1350-9047 *
SAMEL D ET AL: "Generation of a FasL-based proapoptotic fusion protein devoid of systemic toxicity due to cell-surface antigen-restricted activation.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. 22 AUG 2003, vol. 278, no. 34, 22 August 2003 (2003-08-22), pages 32077 - 32082, XP002413361, ISSN: 0021-9258 *
WÜEST THOMAS ET AL: "TNF-Selectokine: a novel prodrug generated for tumor targeting and site-specific activation of tumor necrosis factor.", ONCOGENE. 20 JUN 2002, vol. 21, no. 27, 20 June 2002 (2002-06-20), pages 4257 - 4265, XP002360030, ISSN: 0950-9232 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9169321B2 (en) 2007-08-22 2015-10-27 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof

Also Published As

Publication number Publication date
WO2007014744A2 (en) 2007-02-08
DE102005036542A1 (en) 2007-02-08

Similar Documents

Publication Publication Date Title
WO2007014744A3 (en) C-terminal tnf-family ligand (ctl) -prodrug
YU18903A (en) Fusion protein from antibody cytokine-cytokine inhibitor (selectokine) for use as target-specific prodrug
WO2008031045A3 (en) Aquaretic and natriuretic polypeptides lacking vasodilatory activity
EP2447280A3 (en) VEGF analogs and methods of use
WO2010048308A3 (en) Natriuretic polypeptides
IL187188A0 (en) Improved human interferon molecules and their uses
WO2005081628A3 (en) Casein derived peptides and therapeutic uses thereof
WO2008066752A3 (en) Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
WO2009086126A3 (en) Natriuretic polypeptides
WO2007131092A3 (en) Chimeric t cell receptors and related materials and methods of use
EP3196213A3 (en) Antibodies directed to her-3 and uses thereof
EP2455461A3 (en) Lipase variants for pharmaceutical use
WO2011146518A3 (en) Pegylated c-peptide
EP3597666A3 (en) Compositions, uses and methods for treatment of metabolic disorders and diseases
WO2006023766A3 (en) P450 polynucleotides, polypeptides, and uses thereof
EP1930424A4 (en) Novel apoptosis inducing factor and method of inducing apoptosis using the same
UA103215C2 (en) Polypeptide with xylanase activity
WO2008008482A3 (en) Altered br3-binding polypeptides
PH12014501363A1 (en) Anticancer fusion protein
EP1983003A3 (en) Tyrosine phosphorylation sites and antibodies specific for them
WO2009050277A3 (en) Edta resistant s100a12 complexes (erac)
WO2006023356A3 (en) Selective vpac2 receptor peptide agonists
WO2006060728A3 (en) Methods and compositions involving lcrv proteins
WO2005017188A3 (en) Fusion proteins with a membrane translocating sequence and methods of using same to inhibit an immune response
WO2006083516A3 (en) Modified cyanovirin-n polypeptide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06762913

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载